LPL Financial’s Protara Therapeutics TARA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$188K Buy
36,130
+80
+0.2% +$473 ﹤0.01% 5521
2025
Q4
$192K Hold
36,050
﹤0.01% 5457
2025
Q3
$157K Buy
36,050
+1,050
+3% +$3.4K ﹤0.01% 5414
2025
Q2
$106K Buy
35,000
+12,000
+52% +$41.4K ﹤0.01% 5255
2025
Q1
$98K Sell
23,000
-13,000
-36% -$58.1K ﹤0.01% 5047
2024
Q4
$190K Sell
36,000
-10,000
-22% -$32.3K ﹤0.01% 4827
2024
Q3
$84.2K Buy
46,000
+2,000
+5% +$4.11K ﹤0.01% 4926
2024
Q2
$91.5K Buy
44,000
+16,000
+57% +$46.8K ﹤0.01% 4759
2024
Q1
$112K Buy
28,000
+16,000
+133% +$51.6K ﹤0.01% 4657
2023
Q4
$22.5K Buy
12,000
+2,000
+20% +$2.95K ﹤0.01% 4729
2023
Q3
$16.7K Hold
10,000
﹤0.01% 4620
2023
Q2
$23.9K Sell
10,000
-25
-0.2% -$74 ﹤0.01% 4502
2023
Q1
$31.4K Buy
+10,025
New +$33.1K ﹤0.01% 4371

Other funds holding TARA

LPL Financial's TARA Position: Q1 2026 in Review

LPL Financial increased its Protara Therapeutics (TARA) stake by 0.22% in Q1 2026, buying an estimated $473 and bringing the position to 36,130 shares worth $188K. The position accounts for ﹤0.01% of the portfolio, ranked #5521.

LPL Financial first reported a position in TARA in Q1 2023 and has held it in 13 quarters since. The position peaked at $192K in Q4 2025. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • LPL Financial held 36,130 shares of Protara Therapeutics worth $188K as of Q1 2026.
  • LPL Financial bought 80 Protara Therapeutics shares in Q1 2026, an estimated $473.
  • Protara Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q1 2026, its #5521 holding.
  • LPL Financial first reported a position in Protara Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • LPL Financial's Protara Therapeutics position peaked at $192K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.